Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 40 entries
Sorted by: Best Match Show Resources per page
Prognosis of hospitalized patients with cirrhosis and acute kidney disease.

Liver international : official journal of the International Association for the Study of the Liver

Wong F, Garcia-Tsao G, Reddy KR, O'Leary JG, Kamath PS, Tandon P, Lai JC, Vargas HE, Biggins SW, Fallon MB, Thuluvath PJ, Maliakkal BJ, Subramanian R, Thacker L, Bajaj JS.
PMID: 35023264
Liver Int. 2022 Jan 12; doi: 10.1111/liv.15154. Epub 2022 Jan 12.

The prognosis of acute kidney disease (AKD), defined as a glomerular filtration rate of

Cite
Wong F, Garcia-Tsao G, Reddy KR, et al. Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver Int. 2022;doi: 10.1111/liv.15154.
Wong, F., Garcia-Tsao, G., Reddy, K. R., O'Leary, J. G., Kamath, P. S., Tandon, P., Lai, J. C., Vargas, H. E., Biggins, S. W., Fallon, M. B., Thuluvath, P. J., Maliakkal, B. J., Subramanian, R., Thacker, L., & Bajaj, J. S. (2022). Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver international : official journal of the International Association for the Study of the Liver, . https://doi.org/10.1111/liv.15154
Wong, Florence, et al. "Prognosis of hospitalized patients with cirrhosis and acute kidney disease." Liver international : official journal of the International Association for the Study of the Liver vol. (2022). doi: https://doi.org/10.1111/liv.15154
Wong F, Garcia-Tsao G, Reddy KR, O'Leary JG, Kamath PS, Tandon P, Lai JC, Vargas HE, Biggins SW, Fallon MB, Thuluvath PJ, Maliakkal BJ, Subramanian R, Thacker L, Bajaj JS. Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver Int. 2022 Jan 12; doi: 10.1111/liv.15154. Epub 2022 Jan 12. PMID: 35023264.
Copy Download .nbib Format: NLM
Acute on Chronic Liver Failure: Factors Associated With Transplantation.

Transplantation direct

Goussous N, Xie W, Zhang T, Malik S, Alvarez-Casas J, Gray SH, Barth RN, Thuluvath PJ, LaMattina JC.
PMID: 34805490
Transplant Direct. 2021 Nov 17;7(12):e788. doi: 10.1097/TXD.0000000000001245. eCollection 2021 Dec.

Acute on chronic liver failure (ACLF) carries a poor prognosis unless liver transplantation is offered. We present risk factors associated with proceeding with liver transplantation in patients with ACLF.METHODS: A retrospective review of all patients with ACLF who presented...

Cite
Goussous N, Xie W, Zhang T, et al. Acute on Chronic Liver Failure: Factors Associated With Transplantation. Transplant Direct. 2021;7(12):e788doi: 10.1097/TXD.0000000000001245.
Goussous, N., Xie, W., Zhang, T., Malik, S., Alvarez-Casas, J., Gray, S. H., Barth, R. N., Thuluvath, P. J., & LaMattina, J. C. (2021). Acute on Chronic Liver Failure: Factors Associated With Transplantation. Transplantation direct, 7(12), e788. https://doi.org/10.1097/TXD.0000000000001245
Goussous, Naeem, et al. "Acute on Chronic Liver Failure: Factors Associated With Transplantation." Transplantation direct vol. 7,12 (2021): e788. doi: https://doi.org/10.1097/TXD.0000000000001245
Goussous N, Xie W, Zhang T, Malik S, Alvarez-Casas J, Gray SH, Barth RN, Thuluvath PJ, LaMattina JC. Acute on Chronic Liver Failure: Factors Associated With Transplantation. Transplant Direct. 2021 Nov 17;7(12):e788. doi: 10.1097/TXD.0000000000001245. eCollection 2021 Dec. PMID: 34805490; PMCID: PMC8601355.
Copy Download .nbib Format: NLM
Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome - what we know so far.

World journal of hepatology

Anirvan P, Bharali P, Gogoi M, Thuluvath PJ, Singh SP, Satapathy SK.
PMID: 33442447
World J Hepatol. 2020 Dec 27;12(12):1182-1197. doi: 10.4254/wjh.v12.i12.1182.

The 2019 novel coronavirus disease (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to global public health. Although primarily, the infection causes lung injury, liver enzyme abnormalities have also been reported...

Cite
Anirvan P, Bharali P, Gogoi M, et al. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome - what we know so far. World J Hepatol. 2020;12(12):1182-1197doi: 10.4254/wjh.v12.i12.1182.
Anirvan, P., Bharali, P., Gogoi, M., Thuluvath, P. J., Singh, S. P., & Satapathy, S. K. (2020). Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome - what we know so far. World journal of hepatology, 12(12), 1182-1197. https://doi.org/10.4254/wjh.v12.i12.1182
Anirvan, Prajna, et al. "Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome - what we know so far." World journal of hepatology vol. 12,12 (2020): 1182-1197. doi: https://doi.org/10.4254/wjh.v12.i12.1182
Anirvan P, Bharali P, Gogoi M, Thuluvath PJ, Singh SP, Satapathy SK. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome - what we know so far. World J Hepatol. 2020 Dec 27;12(12):1182-1197. doi: 10.4254/wjh.v12.i12.1182. PMID: 33442447; PMCID: PMC7772728.
Copy Download .nbib Format: NLM
Bariatric Surgery in NAFLD.

Digestive diseases and sciences

Chauhan M, Singh K, Thuluvath PJ.
PMID: 34981313
Dig Dis Sci. 2022 Jan 04; doi: 10.1007/s10620-021-07317-3. Epub 2022 Jan 04.

Currently, there are no approved medications to treat patients with nonalcoholic steatohepatitis (NASH) with fibrosis or cirrhosis. Although the management goal in these patients is weight reduction by 7-10% with lifestyle modifications, only less than 10% of patients achieve...

Cite
Chauhan M, Singh K, Thuluvath PJ. Bariatric Surgery in NAFLD. Dig Dis Sci. 2022;doi: 10.1007/s10620-021-07317-3.
Chauhan, M., Singh, K., & Thuluvath, P. J. (2022). Bariatric Surgery in NAFLD. Digestive diseases and sciences, . https://doi.org/10.1007/s10620-021-07317-3
Chauhan, Mahak, et al. "Bariatric Surgery in NAFLD." Digestive diseases and sciences vol. (2022). doi: https://doi.org/10.1007/s10620-021-07317-3
Chauhan M, Singh K, Thuluvath PJ. Bariatric Surgery in NAFLD. Dig Dis Sci. 2022 Jan 04; doi: 10.1007/s10620-021-07317-3. Epub 2022 Jan 04. PMID: 34981313.
Copy Download .nbib Format: NLM
Mortality and health care burden of Budd Chiari syndrome in the United States: A nationwide analysis (1998-2017).

World journal of hepatology

Alukal JJ, Zhang T, Thuluvath PJ.
PMID: 34239703
World J Hepatol. 2021 Jun 27;13(6):686-698. doi: 10.4254/wjh.v13.i6.686.

BACKGROUND: The Budd Chiari syndrome (BCS) is a rare and potentially fatal disease, but there is a paucity of data on the in- hospital mortality as well its economic burden on the health care system.AIM: To evaluate trends in...

Cite
Alukal JJ, Zhang T, Thuluvath PJ. Mortality and health care burden of Budd Chiari syndrome in the United States: A nationwide analysis (1998-2017). World J Hepatol. 2021;13(6):686-698doi: 10.4254/wjh.v13.i6.686.
Alukal, J. J., Zhang, T., & Thuluvath, P. J. (2021). Mortality and health care burden of Budd Chiari syndrome in the United States: A nationwide analysis (1998-2017). World journal of hepatology, 13(6), 686-698. https://doi.org/10.4254/wjh.v13.i6.686
Alukal, Joseph J, et al. "Mortality and health care burden of Budd Chiari syndrome in the United States: A nationwide analysis (1998-2017)." World journal of hepatology vol. 13,6 (2021): 686-698. doi: https://doi.org/10.4254/wjh.v13.i6.686
Alukal JJ, Zhang T, Thuluvath PJ. Mortality and health care burden of Budd Chiari syndrome in the United States: A nationwide analysis (1998-2017). World J Hepatol. 2021 Jun 27;13(6):686-698. doi: 10.4254/wjh.v13.i6.686. PMID: 34239703; PMCID: PMC8239494.
Copy Download .nbib Format: NLM
Evaluation of Charcot Triad, Reynolds Pentad, and Tokyo Guidelines for Diagnosis of Cholangitis Secondary to Choledocholithiasis Across Patient Age Groups.

Mayo Clinic proceedings. Innovations, quality & outcomes

Thuluvath AJ, Ahn JC, Rattan P, Kurdi AT, Peeraphatdit TB, Kamath MJ, Lennon RJ, Poterucha JJ, Petersen BT, Kamath PS.
PMID: 33997636
Mayo Clin Proc Innov Qual Outcomes. 2021 Apr 08;5(2):377-387. doi: 10.1016/j.mayocpiqo.2021.01.008. eCollection 2021 Apr.

OBJECTIVE: To determine the prevalence of Charcot triad, Reynolds pentad, and Tokyo Guidelines criteria and clinical outcomes among patients with cholangitis across different age groups.PATIENTS AND METHODS: We conducted a retrospective analysis of 257 consecutive hospitalized adult patients with...

Cite
Thuluvath AJ, Ahn JC, Rattan P, et al. Evaluation of Charcot Triad, Reynolds Pentad, and Tokyo Guidelines for Diagnosis of Cholangitis Secondary to Choledocholithiasis Across Patient Age Groups. Mayo Clin Proc Innov Qual Outcomes. 2021;5(2):377-387doi: 10.1016/j.mayocpiqo.2021.01.008.
Thuluvath, A. J., Ahn, J. C., Rattan, P., Kurdi, A. T., Peeraphatdit, T. B., Kamath, M. J., Lennon, R. J., Poterucha, J. J., Petersen, B. T., & Kamath, P. S. (2021). Evaluation of Charcot Triad, Reynolds Pentad, and Tokyo Guidelines for Diagnosis of Cholangitis Secondary to Choledocholithiasis Across Patient Age Groups. Mayo Clinic proceedings. Innovations, quality & outcomes, 5(2), 377-387. https://doi.org/10.1016/j.mayocpiqo.2021.01.008
Thuluvath, Avesh J, et al. "Evaluation of Charcot Triad, Reynolds Pentad, and Tokyo Guidelines for Diagnosis of Cholangitis Secondary to Choledocholithiasis Across Patient Age Groups." Mayo Clinic proceedings. Innovations, quality & outcomes vol. 5,2 (2021): 377-387. doi: https://doi.org/10.1016/j.mayocpiqo.2021.01.008
Thuluvath AJ, Ahn JC, Rattan P, Kurdi AT, Peeraphatdit TB, Kamath MJ, Lennon RJ, Poterucha JJ, Petersen BT, Kamath PS. Evaluation of Charcot Triad, Reynolds Pentad, and Tokyo Guidelines for Diagnosis of Cholangitis Secondary to Choledocholithiasis Across Patient Age Groups. Mayo Clin Proc Innov Qual Outcomes. 2021 Apr 08;5(2):377-387. doi: 10.1016/j.mayocpiqo.2021.01.008. eCollection 2021 Apr. PMID: 33997636; PMCID: PMC8105521.
Copy Download .nbib Format: NLM
O Labeling for a Quantitative Proteomic Analysis of Glycoproteins in Hepatocellular Carcinoma.

Clinical proteomics

Chaerkady R, Thuluvath PJ, Kim MS, Nalli A, Vivekanandan P, Simmers J, Torbenson M, Pandey A.
PMID: 20357908
Clin Proteomics. 2008 Jul 18;4(3):137-155. doi: 10.1007/s12014-008-9013-0.

INTRODUCTION: Quantitative proteomics using tandem mass spectrometry is an attractive approach for identification of potential cancer biomarkers. Fractionation of complex tissue samples into subproteomes prior to mass spectrometric analyses increases the likelihood of identifying cancer-specific proteins that might be...

Cite
Chaerkady R, Thuluvath PJ, Kim MS, et al. O Labeling for a Quantitative Proteomic Analysis of Glycoproteins in Hepatocellular Carcinoma. Clin Proteomics. 2008;4(3):137-155doi: 10.1007/s12014-008-9013-0.
Chaerkady, R., Thuluvath, P. J., Kim, M. S., Nalli, A., Vivekanandan, P., Simmers, J., Torbenson, M., & Pandey, A. (2008). O Labeling for a Quantitative Proteomic Analysis of Glycoproteins in Hepatocellular Carcinoma. Clinical proteomics, 4(3), 137-155. https://doi.org/10.1007/s12014-008-9013-0
Chaerkady, Raghothama, et al. "O Labeling for a Quantitative Proteomic Analysis of Glycoproteins in Hepatocellular Carcinoma." Clinical proteomics vol. 4,3 (2008): 137-155. doi: https://doi.org/10.1007/s12014-008-9013-0
Chaerkady R, Thuluvath PJ, Kim MS, Nalli A, Vivekanandan P, Simmers J, Torbenson M, Pandey A. O Labeling for a Quantitative Proteomic Analysis of Glycoproteins in Hepatocellular Carcinoma. Clin Proteomics. 2008 Jul 18;4(3):137-155. doi: 10.1007/s12014-008-9013-0. PMID: 20357908; PMCID: PMC2847390.
Copy Download .nbib Format: NLM
Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments.

Journal of clinical and experimental hepatology

Thuluvath PJ, Nuthalapati A, Price J, Maheshwari A.
PMID: 27194889
J Clin Exp Hepatol. 2016 Mar;6(1):3-9. doi: 10.1016/j.jceh.2015.09.003. Epub 2015 Oct 03.

BACKGROUND: Minimal hepatic encephalopathy (MHE) may adversely affect driving skills.AIMS: To compare the driving performance of cirrhotic patients with and without prior HE as well as controls using a driving stimulator and to correlate psychometric testing with driving performance.METHODS:...

Cite
Thuluvath PJ, Nuthalapati A, Price J, et al. Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments. J Clin Exp Hepatol. 2015;6(1):3-9doi: 10.1016/j.jceh.2015.09.003.
Thuluvath, P. J., Nuthalapati, A., Price, J., & Maheshwari, A. (2016). Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments. Journal of clinical and experimental hepatology, 6(1), 3-9. https://doi.org/10.1016/j.jceh.2015.09.003
Thuluvath, Paul J, et al. "Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments." Journal of clinical and experimental hepatology vol. 6,1 (2016): 3-9. doi: https://doi.org/10.1016/j.jceh.2015.09.003
Thuluvath PJ, Nuthalapati A, Price J, Maheshwari A. Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments. J Clin Exp Hepatol. 2016 Mar;6(1):3-9. doi: 10.1016/j.jceh.2015.09.003. Epub 2015 Oct 03. PMID: 27194889; PMCID: PMC4862017.
Copy Download .nbib Format: NLM
Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!".

Journal of hepatology

Thuluvath PJ, Li F.
PMID: 34666069
J Hepatol. 2022 Jan;76(1):242-243. doi: 10.1016/j.jhep.2021.10.007. Epub 2021 Oct 16.

No abstract available.

Cite
Thuluvath PJ, Li F. Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!". J Hepatol. 2021;76(1):242-243doi: 10.1016/j.jhep.2021.10.007.
Thuluvath, P. J., & Li, F. (2022). Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!". Journal of hepatology, 76(1), 242-243. https://doi.org/10.1016/j.jhep.2021.10.007
Thuluvath, Paul J, and Li, Feng. "Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!"." Journal of hepatology vol. 76,1 (2022): 242-243. doi: https://doi.org/10.1016/j.jhep.2021.10.007
Thuluvath PJ, Li F. Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!". J Hepatol. 2022 Jan;76(1):242-243. doi: 10.1016/j.jhep.2021.10.007. Epub 2021 Oct 16. PMID: 34666069.
Copy Download .nbib Format: NLM
Gender and ethnic differences in the post-liver transplant outcomes of patients with autoimmune hepatitis with acute liver failure at initial presentation: a case-control study.

Archives of medical science : AMS

Thuluvath PJ, Wagennar RR, Verma S.
PMID: 26788084
Arch Med Sci. 2015 Dec 10;11(6):1227-35. doi: 10.5114/aoms.2015.52736. Epub 2015 Dec 11.

INTRODUCTION: Autoimmune hepatitis (AIH) may initially present as acute liver failure (ALF). The outcome of liver transplantation (LT) in patients with AIH and ALF is not very well defined. We determined the outcome of LT in UNOS (United Network...

Cite
Thuluvath PJ, Wagennar RR, Verma S. Gender and ethnic differences in the post-liver transplant outcomes of patients with autoimmune hepatitis with acute liver failure at initial presentation: a case-control study. Arch Med Sci. 2015;11(6):1227-35doi: 10.5114/aoms.2015.52736.
Thuluvath, P. J., Wagennar, R. R., & Verma, S. (2015). Gender and ethnic differences in the post-liver transplant outcomes of patients with autoimmune hepatitis with acute liver failure at initial presentation: a case-control study. Archives of medical science : AMS, 11(6), 1227-35. https://doi.org/10.5114/aoms.2015.52736
Thuluvath, Paul J, et al. "Gender and ethnic differences in the post-liver transplant outcomes of patients with autoimmune hepatitis with acute liver failure at initial presentation: a case-control study." Archives of medical science : AMS vol. 11,6 (2015): 1227-35. doi: https://doi.org/10.5114/aoms.2015.52736
Thuluvath PJ, Wagennar RR, Verma S. Gender and ethnic differences in the post-liver transplant outcomes of patients with autoimmune hepatitis with acute liver failure at initial presentation: a case-control study. Arch Med Sci. 2015 Dec 10;11(6):1227-35. doi: 10.5114/aoms.2015.52736. Epub 2015 Dec 11. PMID: 26788084; PMCID: PMC4697044.
Copy Download .nbib Format: NLM
Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.

Journal of clinical and experimental hepatology

Doycheva I, Thuluvath PJ.
PMID: 31695249
J Clin Exp Hepatol. 2019 Sep-Oct;9(5):588-596. doi: 10.1016/j.jceh.2019.07.012. Epub 2019 Aug 02.

Hepatocellular carcinoma (HCC) incidence and mortality have shown an unfavorable upward trend over the last two decades, especially in developed countries. More than one-sixth of the patients have advanced HCC at presentation. Systemic therapy remains the treatment of choice...

Cite
Doycheva I, Thuluvath PJ. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. J Clin Exp Hepatol. 2019;9(5):588-596doi: 10.1016/j.jceh.2019.07.012.
Doycheva, I., & Thuluvath, P. J. (2019). Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. Journal of clinical and experimental hepatology, 9(5), 588-596. https://doi.org/10.1016/j.jceh.2019.07.012
Doycheva, Iliana, and Thuluvath, Paul J. "Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field." Journal of clinical and experimental hepatology vol. 9,5 (2019): 588-596. doi: https://doi.org/10.1016/j.jceh.2019.07.012
Doycheva I, Thuluvath PJ. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. J Clin Exp Hepatol. 2019 Sep-Oct;9(5):588-596. doi: 10.1016/j.jceh.2019.07.012. Epub 2019 Aug 02. PMID: 31695249; PMCID: PMC6823698.
Copy Download .nbib Format: NLM
REPLY.

Hepatology (Baltimore, Md.)

Kovalic AJ, Huang G, Thuluvath PJ, Satapathy SK.
PMID: 32895966
Hepatology. 2021 May;73(5):2080-2081. doi: 10.1002/hep.31542. Epub 2021 Apr 26.

No abstract available.

Cite
Kovalic AJ, Huang G, Thuluvath PJ, et al. REPLY. Hepatology. 2021;73(5):2080-2081doi: 10.1002/hep.31542.
Kovalic, A. J., Huang, G., Thuluvath, P. J., & Satapathy, S. K. (2021). REPLY. Hepatology (Baltimore, Md.), 73(5), 2080-2081. https://doi.org/10.1002/hep.31542
Kovalic, Alexander J, et al. "REPLY." Hepatology (Baltimore, Md.) vol. 73,5 (2021): 2080-2081. doi: https://doi.org/10.1002/hep.31542
Kovalic AJ, Huang G, Thuluvath PJ, Satapathy SK. REPLY. Hepatology. 2021 May;73(5):2080-2081. doi: 10.1002/hep.31542. Epub 2021 Apr 26. PMID: 32895966.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 40 entries